Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers.Methods: Aiming to th...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |